AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15577788 — intervention group
Group type: EXPERIMENTAL
Intervention: Envoy System
Number of subjects: 7
Study 11805557 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60
Study 11805557 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 60
Study 9218237 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation training facilitated through biofeedback
Number of subjects: 0
Study 9218237 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving autogenic relaxation training)
Number of subjects: 0
Study 7510078 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐506 intelligent dosing system (IDS)
Number of subjects: 0
Study 7510078 — intervention group
Group type: EXPERIMENTAL
Intervention: RCCCT design guided by IDS
Number of subjects: 0
Study 2133624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g Mg pidolate (MAG2) three times a day for one month
Number of subjects: 38
Study 2133624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18071 — intervention group
Group type: EXPERIMENTAL
Intervention: IM lorazepam
Number of subjects: 40
Study 18071 — intervention group
Group type: COMPARATOR
Intervention: IM pentobarbital
Number of subjects: 40
Study 30311367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg per day)
Number of subjects: 71
Study 30311367 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 71
Study 28588304 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 181
Study 28588304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie (LC) diet
Number of subjects: 181
Study 28588304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 181
Study 28588304 — intervention group
Group type: COMPARATOR
Intervention: Energy-restriction treatments (VLCK and LC diets)
Number of subjects: 181
Study 25156879 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of salbutamol
Number of subjects: 21
Study 23172751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupuzor (200 μg) subcutaneously every 4 weeks
Number of subjects: 149
Study 23172751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupuzor (200 μg) subcutaneously every 2 weeks
Number of subjects: 149
Study 23172751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 21804623 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 0
Study 21804623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19309420 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention training parents to work with children through modelling and coaching by teachers during weekly home visits
Number of subjects: 30
Study 19309420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 16397402 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT2A -1438 A/G polymorphism
Number of subjects: 132
Study 16397402 — intervention group
Group type: COMPARATOR
Intervention: 5‐HTTLPR
Number of subjects: 132
Study 15622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids
Number of subjects: 156
Study 15622574 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 156
Study 11694205 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cessation intervention
Number of subjects: 200
Study 11694205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 9220527 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol delivered from an MDI with a valved spacer (Aerochamber)
Number of subjects: 13
Study 9220527 — intervention group
Group type: COMPARATOR
Intervention: 600 micrograms salbutamol delivered via jet nebulizer (PariBaby)
Number of subjects: 13
Study 8237402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin tablet (400 mg)
Number of subjects: 10
Study 8237402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin capsule (400 mg)
Number of subjects: 10
Study 3524844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociverine 20 mg
Number of subjects: 40
Study 3524844 — intervention group
Group type: COMPARATOR
Intervention: Flavoxate 200 mg
Number of subjects: 40
Study 29701091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 321
Study 29701091 — intervention group
Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 321
Study 27604774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-protein infant formula (LPF)
Number of subjects: 1882
Study 27604774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-protein infant formula with additional active ingredients (LPFA)
Number of subjects: 1882
Study 27604774 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 1882
Study 23034126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with normal saline
Number of subjects: 60
Study 23034126 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigation group
Number of subjects: 60
Study 23796998 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg for 19 doses over 5 years)
Number of subjects: 3360
Study 23796998 — intervention group
Group type: COMPARATOR
Intervention: Control (standard adjuvant systemic therapy alone)
Number of subjects: 3360
Study 20842110 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg daily for 4 weeks
Number of subjects: 808
Study 20842110 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued current therapy)
Number of subjects: 808
Study 20842110 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 808
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 14237
Study 18613278 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or active diabetes medications)
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy versus placebo
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy versus sulfonylurea/metformin monotherapy
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea + rosiglitazone versus sulfonylurea monotherapy
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + rosiglitazone versus metformin monotherapy
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + rosiglitazone versus metformin + sulfonylurea
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea + metformin + rosiglitazone versus sulfonylurea + metformin
Number of subjects: 14237
Study 18613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + rosiglitazone versus insulin monotherapy
Number of subjects: 14237
Study 15705433 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress inlays and onlays
Number of subjects: 34
Study 12849762 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa therapy (ON condition)
Number of subjects: 18
Study 12849762 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (OFF condition)
Number of subjects: 18
Study 12849762 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy subjects)
Number of subjects: 18
Study 10383543 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6% SAZN
Number of subjects: 24
Study 10383543 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% SAZN
Number of subjects: 24
Study 10383543 — intervention group
Group type: COMPARATOR
Intervention: Diprivan-10
Number of subjects: 24
Study 10383543 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 24
Study 9060777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring/Old
Number of subjects: 135
Study 9060777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring/New
Number of subjects: 135
Study 9060777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care/Old
Number of subjects: 135
Study 9060777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care/New
Number of subjects: 135
Study 1702795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 6685863 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving informed consent (after giving consent)
Number of subjects: 628
Study 6685863 — intervention group
Group type: COMPARATOR
Intervention: Receiving standard disclosure (before receiving consent)
Number of subjects: 628
Study 6685863 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent obtained just prior to discharge
Number of subjects: 628
Study 30455075 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 200
Study 30455075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29920978 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5 to 20 mg once daily)
Number of subjects: 0
Study 26885925 — intervention group
Group type: EXPERIMENTAL
Intervention: HMF group (n=62)
Number of subjects: 122
Study 24490977 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination (GSD) intervention
Number of subjects: 120
Study 22324948 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg weekly
Number of subjects: 41
Study 22324948 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) 150 mg daily
Number of subjects: 41
Study 19586140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 28
Study 19586140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 100
Study 17335316 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 100
Study 17335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination trials (antidepressant and antipsychotic)
Number of subjects: 100
Study 15064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 micro g*kg(‐1) iv followed by 0.5 micro g*kg(‐1)*hr(‐1) infusion with morphine PCA (2 mg bolus, five minutes lockout, 2 mg*hr(‐1) infusion)
Number of subjects: 60
Study 15064262 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 1.5 mg*kg(‐1) pre‐mixed with midazolam 30 micro g*kg(‐1) iv followed by tramadol PCA (20 mg bolus, five minute lockout, 20 mg*hr(‐1) infusion)
Number of subjects: 60
Study 12126906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine (Group A: 50,000 PFU, Group B: 16,000 PFU)
Number of subjects: 100
Study 12126906 — intervention group
Group type: COMPARATOR
Intervention: VARILRIX (Group C: 40,000 PFU)
Number of subjects: 100
Study 9614452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis during pregnancy
Number of subjects: 0
Study 7861197 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim 200mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Number of subjects: 56
Study 7861197 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Number of subjects: 56
Study 7861197 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 56
Study 7861197 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 56
Study 2782122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to palatable food stimuli
Number of subjects: 0
Study 2782122 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no food during exposure)
Number of subjects: 0
Study 2782122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreferred food presented during exposure phase
Number of subjects: 0
Study 58563 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 per cent Dextran 60
Number of subjects: 0
Study 58563 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 per cent hydroxyethyl starch (HES)
Number of subjects: 0
Study 31137125 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time training including face-to-face lectures and hand-by-hand operation training course
Number of subjects: 28
Study 31137125 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28
Study 31137125 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time training
Number of subjects: 28
Study 28318515 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin administration 24 hours or less preoperatively
Number of subjects: 3025
Study 28318515 — intervention group
Group type: COMPARATOR
Intervention: Statin administration 24 to 72 hours preoperatively
Number of subjects: 3025
Study 28318515 — intervention group
Group type: COMPARATOR
Intervention: Statin administration more than 72 hours or no dose
Number of subjects: 3025
Study 28318515 — intervention group
Group type: COMPARATOR
Intervention: Statin dose of 20 mg or less
Number of subjects: 3025
Study 28318515 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin dose of more than 20 mg
Number of subjects: 3025
Study 28318515 — intervention group
Group type: COMPARATOR
Intervention: No preoperative statin
Number of subjects: 3025
Study 25061037 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 96
Study 25061037 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 96
Study 25061037 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback Posture Trainer (Backtone)
Number of subjects: 96
Study 25061037 — intervention group
Group type: COMPARATOR
Intervention: Postural Education (Control)
Number of subjects: 96
Study 23731498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing for CYP450 2D6 and 2C19
Number of subjects: 207
Study 23731498 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 207
Study 21567258 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 102
Study 21567258 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 102
Study 21567258 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-Secur
Number of subjects: 102
Study 18577154 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 18577154 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16901644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2 receptor agonist)
Number of subjects: 24
Study 16901644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14604600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 12
Study 14604600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11709645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 95
Study 11709645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with standard cycle (30 seconds)
Number of subjects: 95
Study 9387945 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 19
Study 9387945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7639374 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural infusion of 2% lidocaine
Number of subjects: 14
Study 7639374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3281916 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 38
Study 3281916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31228006 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.0, 1.5, and 1.2 mg/kg for young, middle, and elderly groups respectively)
Number of subjects: 60
Study 31228006 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5.0, 4.0, and 3.0 mg/kg for young, middle, and elderly groups respectively)
Number of subjects: 60
Study 31228006 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 28877109 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic foam overlay (VEFO) on top of the standard hospital mattress
Number of subjects: 110
Study 28877109 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress with/without air overlay
Number of subjects: 110
Study 28877109 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic foam overlay (VEFO)
Number of subjects: 110
Study 28877109 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 110
Study 25158925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (48 μg/day) for 4 weeks
Number of subjects: 124
Study 25158925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 25158925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 μg twice daily) for 48 weeks
Number of subjects: 124
Study 24096771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of miR‐487b
Number of subjects: 0
Study 24096771 — intervention group
Group type: EXPERIMENTAL
Intervention: Upregulation of miR‐487b
Number of subjects: 0
Study 24096771 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion
Number of subjects: 0
Study 21461761 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8
Study 21461761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 mg/kg)
Number of subjects: 8
Study 18047576 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O/O(2) plus local anaesthetic (LA)
Number of subjects: 48
Study 18047576 — intervention group
Group type: COMPARATOR
Intervention: Oxygen plus local anaesthetic (LA)
Number of subjects: 48
Study 18047576 — intervention group
Group type: COMPARATOR
Intervention: N(2)O/O(2) plus LA and Oxygen plus LA
Number of subjects: 48
Study 16929603 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented ureteroscopic lithotripsy (6 ch DJ stent)
Number of subjects: 56
Study 16929603 — intervention group
Group type: COMPARATOR
Intervention: Non-stented ureteroscopic lithotripsy
Number of subjects: 56
Study 14643532 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENAR plus DTP-IPV/Hib
Number of subjects: 0
Study 14643532 — intervention group
Group type: COMPARATOR
Intervention: DTP-IPV/Hib alone
Number of subjects: 0
Study 11153048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise at 50% peak oxygen uptake
Number of subjects: 53
Study 11153048 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (control session)
Number of subjects: 53
Study 8616131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 196
Study 8616131 — intervention group
Group type: COMPARATOR
Intervention: Resection
Number of subjects: 196
Study 1486524 — intervention group
Group type: EXPERIMENTAL
Intervention: School dental screening intervention (advised by letter for detailed clinical examination)
Number of subjects: 528
Study 1486524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 528
Study 2418707 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 Units of Heparin/kg body weight injected into the right atrium (group 1)
Number of subjects: 32
Study 2418707 — intervention group
Group type: COMPARATOR
Intervention: 375 Units of Heparin/kg body weight injected into the ascending aorta (group 2)
Number of subjects: 32
Study 30883159 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of weight diversity among same-sex peers at school
Number of subjects: 5991
Study 29371133 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline (HS), 7% NaCl, 4 mL, single dose
Number of subjects: 0
Study 29371133 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 0
Study 29371133 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes after HS
Number of subjects: 0
Study 27347698 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (10 sessions)
Number of subjects: 64
Study 27347698 — intervention group
Group type: COMPARATOR
Intervention: Classic massage (10 sessions)
Number of subjects: 64
Study 25152289 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg/kg (Group II)
Number of subjects: 120
Study 25152289 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.075 mg/kg (Group III)
Number of subjects: 120
Study 25152289 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.1 mg/kg (Group IV)
Number of subjects: 120
Study 25152289 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection (Group I)
Number of subjects: 120
Study 22580353 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (Consepsis)
Number of subjects: 40
Study 22580353 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40
Study 20507898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 236
Study 18154225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive educational programme including topical application of 1.23% acidulated fluoride phosphate, pH 3.5, every 6 months
Number of subjects: 58
Study 18154225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study 15638902 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral buffered pH (NaH(2)PO(4) buffered to pH 7.5)
Number of subjects: 26
Study 15638902 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological pH (5.0)
Number of subjects: 26
Study 15638902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26
Study 12017398 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 13
Study 10361960 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg)
Number of subjects: 126